Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- BARKER ON DRUGS (10)
November 18, 2002
- BARKER ON DRUGS (9)
October 14, 2002
- Commentary 2 articles
October 7, 2002
- Barker on Drugs (8)
September 9, 2002
- Barkers on Drugs (7)
July 29, 2002
- BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
- BARKER ON DRUGS(5)
June 3, 2002
- BARKER ON DRUGS(4)
April 22, 2002
- Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
- BARKER ON DRUGS (3)
March 11, 2002
- BARKER ON DRUGS
February 18, 2002
- Comarketing as a Marketing Strategy Option -1-
January 21, 2002
- Comarketing as a Marketing Strategy Option -2-
January 21, 2002
- Barker on Drugs (1)
January 14, 2002
- Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan
July 9, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-
May 21, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -1-
May 21, 2001
- Forecasting JapaneseDrug Industry Growth in FY2001
March 26, 2001
- -1-
February 26, 2001
- -2-
February 26, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…